Providing products asked by clinicians about patients suffering from relatively rare indications/diseases or specific diagnosis, staging, prognosis and therapeutic monitoring

Mediam is a pharmaceutical company specialised on the commercialisation of niche markets. We provide products asked by clinicians about patients suffering from relatively rare indications/diseases or specific diagnosis, staging, prognosis and therapeutic monitoring.

Mediam was founded in 2000 . The company has obtained the first Orphan Medicine Product Status granted by the EMEA . We have also developped a strong relationship for a licensing out with a Big Pharma ie. acquisition of Cholediam (mebrofenin) from IBA formely (CisBio - Cholecis), acquisition of Hepatate (stannous floride - tin colloid) from GE and more recently Stannous Agent. All are dedicated to the Nuclear Medecine field.

We are present with marketing approvals in Europe (UK, Ireland, France etc.) and we also market our products in Asia and Middle East territories.

  MEDIAM PHARMA

  85 rue N. Mandela

  F-59120 Loos

  Phone : +33 (0)3 20 49 72 58

  Fax : +33 (0)3 20 88 16 71

  mail : contact@mediam-pharma.com

Products

CHOLEDIAM (Mebrofenin)

HEPATATE (Stannous Fluoride/Tin colloid )